EVFM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EVFM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Evofem Biosciences's yield on cost for the quarter that ended in Dec. 2023 was 0.00.
The historical rank and industry rank for Evofem Biosciences's 5-Year Yield-on-Cost % or its related term are showing as below:
For the Biotechnology subindustry, Evofem Biosciences's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Evofem Biosciences's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Evofem Biosciences's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Evofem Biosciences is calculated as
Yield-on-Cost | = | Dividend Yield % | * | (1 | + | Dividend Growth Rate)^5 |
Evofem Biosciences (OTCPK:EVFM) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Thank you for viewing the detailed overview of Evofem Biosciences's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.
Yan Zhang | officer: Chief Financial Officer | 6166 TIKI CT, SAN DIEGO CA 92130 |
Kim P. Kamdar | director, 10 percent owner | C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542 |
Jenny C. Yip | director | 12400 HIGH BLUFF DR., STE. 600, SAN DIEGO CA 92130 |
Atkinson Katherine Cocca | officer: Chief Commercial Officer | 12400 HIGH BLUFF., STE. 600, SAN DIEGO CA 92130 |
Saundra L Pelletier | director, officer: Chief Executive Officer | C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130 |
Alexander A Fitzpatrick | officer: General Counsel and Secretary | 9605 SCRANTON ROAD, SUITE 200, SAN DIEGO CA 92121 |
Justin J. File | officer: Chief Financial Officer | C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130 |
Anthony Stephen O'brien | director | C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130 |
Russell Barrans | officer: Chief Commercial Officer | C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130 |
Lisa Dale Rarick | director | C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, STE 600, SAN DIEGO CA 92130 |
William Walmsley Hall | director | C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DIRVE, SUITE 600, SAN DIEGO CA 92130 |
Invesco Ltd. | 10 percent owner | 1331 SPRING STREET NW, SUITE 2500, ATLANTA GA 30309 |
Link Fund Solutions Ltd | 10 percent owner | 65 GRESHAM STREET, LONDON X0 EC2V 7NQ |
Acacia Research Corp | 10 percent owner | 767 3RD AVENUE, 6TH FLOOR, NEW YORK NY 10017 |
Kelly Culwell | officer: Chief Medical Officer | C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130 |
From GuruFocus
By PRNewswire PRNewswire • 04-12-2023
By PRNewswire • 08-14-2023
By PRNewswire • 08-22-2023
By PRNewswire • 12-12-2023
By PRNewswire PRNewswire • 07-28-2022
By PRNewswire PRNewswire • 08-01-2022
By PRNewswire PRNewswire • 06-01-2023
By PRNewswire • 10-24-2023
By PRNewswire PRNewswire • 07-26-2022
By PRNewswire PRNewswire • 07-25-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.